Kyntra Bio
KYNB
171 hedge funds and large institutions have $1.42B invested in Kyntra Bio in 2023 Q1 according to their latest regulatory filings, with 40 funds opening new positions, 48 increasing their positions, 60 reducing their positions, and 12 closing their positions.
424% more call options, than puts
Call options by funds: $41.6M | Put options by funds: $7.94M
233% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 12
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
20% more funds holding
Funds holding: 143 → 171 (+28)
19% more capital invested
Capital invested by funds: $1.2B → $1.42B (+$227M)
0.06% more ownership
Funds ownership: 3.18% → 3.24% (+0.06%)
20% less repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 60
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Artisan Partners
Milwaukee,
Wisconsin
|
+$28.6M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$28.5M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$26.7M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$20.3M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$38.1M |
| 2 |
AC
Armistice Capital
New York
|
-$32.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$28.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$13M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$12.1M |
KYNB Hedge Fund Activity: Q1 2023 in Review
171 of the 6,282 institutional investors tracked by Wall St. Rank reported a position in Kyntra Bio (KYNB) for Q1 2023, worth a combined $1.42B — up 19% from $1.2B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new KYNB positions and 12 closed out — a net gain of 28 holders — while 48 added to existing stakes and 60 trimmed.
The largest buyer was Artisan Partners, opening a new position worth an estimated $28.6M. The largest seller was Adage Capital Partners, cutting an estimated $38.1M.
- 171 institutional investors held Kyntra Bio (KYNB) as of Q1 2023, up from 143 in Q4 2022.
- Funds reported $1.42B of Kyntra Bio stock for Q1 2023, up 19% quarter-over-quarter.
- 40 funds opened new Kyntra Bio positions in Q1 2023 and 12 closed out, a net change of +28 holders.
- The largest Kyntra Bio buyer in Q1 2023 was Artisan Partners, an estimated $28.6M added.
- The largest Kyntra Bio seller in Q1 2023 was Adage Capital Partners, an estimated $38.1M sold.
Based on aggregated 13F filings for Q1 2023.